[Prospective and comparative study of 2 antibiotic therapy protocols in 66 febrile neutropenic patients. Ceftazidime-vancomycin versus ticarcillin-vancomycin-amikacin].
Out of 66 febrile neutropenic patients, 33 were treated with a ceftazidime-vancomycin combination (group A) and 33 with a ticarcillin-vancomycin-amikacin combination (group B). There was no significant difference in satisfactory results between the two groups (group A 79 per cent, group B 88 per cent), and both regimens were equally active in all febrile episodes. Reversible side-effects (renal and cutaneous toxicity) were observed in 15 per cent of the cases. Two cases of superinfection and one case of resistance occurring during treatment were noted in group B patients. At a time when Gram-positive infections are increasingly frequent among febrile neutropenic patients, the ceftazidime-vancomycin combination seems to be as effective as the ticarcillin-vancomycin-amikacin triple drug combination.
Brion
J P
JP
Service des Maladies infectieuses, Centre hospitalier Albert Michallon, La Tronche.
Bru
J P
JP
Michallet
M
M
Corron
B
B
Fauconnier
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000150:complications*; D000583:Amikacin / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005334:Fever / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications*; D010406:Penicillins / Q000627:therapeutic use*; D011446:Prospective Studies; D013982:Ticarcillin / Q000627:therapeutic use*; D014640:Vancomycin / Q000627:therapeutic use*
D010406:Penicillins; D014640:Vancomycin; D000583:Amikacin; D002442:Ceftazidime; D013982:Ticarcillin
Etude prospective et comparative de deux protocoles d'antibiothérapie chez 66 malades neutropéniques fébriles. Ceftazidime-vancomycine versus ticarcilline-vancomycine-amikacine.